Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the breast-cancer desk.
health
In the phase 2 PHERGain trial, a PET- and pathology-guided strategy had an estimated five-year invasive disease-free survival of 89.5% among patients assigned to the adaptive-treatment group who underwent surgery. Exploratory ctDNA analyses linked early clearance with higher pathological complete response rates and better five-year outcomes.
health
A bioRxiv preprint reports that ANO6 helps organize contacts between the endoplasmic reticulum and mitochondria, directing vulnerable lipids into protective droplets in chemoresistant breast cancer models. Disrupting the system with niclosamide resensitized models to ferroptosis.
science
A bioRxiv preprint reports that tumour-cell states, mutations, tumour architecture and immune signals were associated with differences in ctDNA release in ten patients with non-metastatic HR+/HER2− breast cancer. The findings offer a biological framework for understanding why tumour DNA detected in tissue may differ from what appears in blood.
health
A bioRxiv preprint associates a platelet-related circulating tumour-cell profile in breast cancer with poorer overall survival. It also proposes a CD40LG–ITGA5:ITGB1 signal involving monocytes as a candidate for further study.
health
NHS England will make trastuzumab deruxtecan, sold as Enhertu, available to around 1,000 women with HER2-low advanced or metastatic breast cancer after their disease progresses following treatment.